Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-20 5:16 pm Purchase |
2025-03-07 | 13D | TransCode Therapeutics, Inc. RNAZ |
Thomas Joseph Tracy | 35,000 5.000% |
35,000 (New Position) |
Filing History |
| 2025-02-14 5:16 pm Purchase |
2024-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
Anson Funds Management LP | 113,479 9.900% |
113,479 (New Position) |
Filing History |
| 2025-01-03 7:25 pm Purchase |
2024-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
SABBY MANAGEMENT LLC | 69,555 9.900% |
69,555 (New Position) |
Filing History |
| 2024-11-06 4:05 pm Sale |
2024-09-30 | 13G | TransCode Therapeutics, Inc. RNAZ |
3i, LP | 0 0.000% |
-52,018 (Position Closed) |
Filing History |
| 2024-07-26 4:05 pm Purchase |
2024-07-23 | 13G | TransCode Therapeutics, Inc. RNAZ |
3i, LP | 52,018 9.900% |
52,018 (New Position) |
Filing History |
| 2024-06-21 4:02 pm Purchase |
2024-06-14 | 13D | TransCode Therapeutics, Inc. RNAZ |
Fitzgerald Thomas A | 12,789 5.500% |
12,789 (New Position) |
Filing History |
| 2024-02-15 4:00 pm Purchase |
2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
Medarova Zdravka | 3,396 0.400% |
3,396 (New Position) |
Filing History |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-269 (Position Closed) |
Filing History |
| 2024-02-13 8:12 pm Sale |
2023-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
Lind Global Fund II LP | 796 0.100% |
-1,098 (-57.95%) |
Filing History |
| 2023-12-07 4:30 pm Purchase |
2023-12-04 | 13G | TransCode Therapeutics, Inc. RNAZ |
Lind Global Fund II LP | 1,894 9.900% |
1,894 (New Position) |
Filing History |
| 2023-10-10 4:00 pm Purchase |
2023-09-28 | 13D | TransCode Therapeutics, Inc. RNAZ |
Dudley Robert Michael | 173 1.900% |
88 (+104.19%) |
Filing History |
| 2023-09-26 11:06 am Purchase |
2023-09-26 | 13G | TransCode Therapeutics, Inc. RNAZ |
TANG CAPITAL PARTNERS LP | 269 9.990% |
269 (New Position) |
Filing History |
| 2023-06-16 4:00 pm Purchase |
2023-06-09 | 13D | TransCode Therapeutics, Inc. RNAZ |
Dudley Robert Michael | 84 6.000% |
84 (New Position) |
Filing History |
| 2023-02-10 08:00 am Purchase |
2022-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
Medarova Zdravka | 63 12.700% |
2 (+2.61%) |
Filing History |
| 2022-12-19 5:36 pm Purchase |
2022-10-01 | 13D | TransCode Therapeutics, Inc. RNAZ |
Dudley Robert Michael | 67 12.700% |
12 (+22.54%) |
Filing History |
| 2022-12-19 5:33 pm Purchase |
2021-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
Medarova Zdravka | 61 12.500% |
61 (New Position) |
Filing History |
| 2022-12-19 5:32 pm Purchase |
2021-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
Dudley Robert Michael | 54 10.600% |
54 (New Position) |
Filing History |
| 2022-10-27 08:08 am Sale |
2022-10-26 | 13G | TransCode Therapeutics, Inc. RNAZ |
HIRSCHMAN ORIN | 0 0.000% |
-49 (Position Closed) |
Filing History |
| 2022-02-11 3:06 pm Purchase |
2021-12-31 | 13G | TransCode Therapeutics, Inc. RNAZ |
HIRSCHMAN ORIN | 49 9.900% |
1 (+1.46%) |
Filing History |
| 2021-07-20 5:55 pm Purchase |
2021-07-09 | 13G | TransCode Therapeutics, Inc. RNAZ |
HIRSCHMAN ORIN | 48 9.900% |
48 (New Position) |
Filing History |